Cancer Imaging · 2021 · 17 citations · 14 references
MedicineNuclear MedicineOncologyDiagnostic ImagingDiagnostic RadiologyImmunotherapyCancer ImmunotherapyImmunotherapy For Skin CancerOncologic Nuclear ImagingPositron Emission TomographyResponse AssessmentTherapy Response AssessmentAdvanced Cutaneous Squamous Cell Carcinoma TherapyImaging Response CriteriaImaging Response EvaluationImmunotherapy Response AssessmentPositron Emission Tomography Response AssessmentResponse To ImmunotherapyTherapy Response EvaluationTumor Response Evaluation
BACKGROUND: The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months. METHODS: This was a single-centre retrospective study of 15 patients treated with cemiplimab for advanced CSCC who had CT/MRI and FDG-PET/CT at > 10 months to assess metabolic treatment response. The median age was 73 years (range 55-84) and 93% were male. RECIST1.1 and PERCIST1.0 tumor responses were evaluated by blinded readers. RESULTS: Seventy-three percent (11/15) (95%CI 44.9, 92.2%) achieved a CMR on PET. Of these 11, on RECIST1.1 there was one complete response, 9 partial responses and one stable disease. CONCLUSIONS: In patients on cemiplimab for > 10 months, there was discordance between CR rates on FDG-PET versus RECIST1.1. FDG-PET/CT may have utility for clarifying depth of response in patients treated with immunotherapy for CSCC.
14
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations